Candesartan Adjunctive Depression for depression in bipolarity

This study is exploring medication or study treatment for people with bipolarity. Participants may complete study visits, assessments, or follow-up activities defined by the research team. It includes a comparison with placebo. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

This appears to be a medication / drug study involving Candesartan, Placebo. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.

This study may concern people with bipolarity; age range: Over 18 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.

You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

This study is sponsored by Deakin University, which appears to be a university. Listed collaborators include University of Melbourne, University of Sydney, Barwon Health, Eastern Health, The Melbourne Clinic, Albert Road Clinic, Royal North Shore Hospital, Toowong Specialist Clinic. The listed contact or investigator is Prof Michael Berk, affiliated with Deakin University. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

The registry indicates that this study is currently recruiting. This does not mean you are eligible: the study team must confirm the criteria, available locations, and next steps. The registry lists an estimated enrollment of 240 participants.